Scientific paper - Review paper
Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
Cardiovascular Therapeutics, 2022 (2022); 8129513. https://doi.org/10.1155/2022/8129513

Merćep, Iveta; Friščić, Nikolina; Strikić, Dominik; Reiner, Željko

Cite this document

Merćep, I., Friščić, N., Strikić, D. & Reiner, Ž. (2022). Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review. Cardiovascular Therapeutics, 2022.. doi: 10.1155/2022/8129513

Merćep, Iveta, et al. "Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review." Cardiovascular Therapeutics, vol. 2022, 2022. https://doi.org/10.1155/2022/8129513

Merćep, Iveta, Nikolina Friščić, Dominik Strikić and Željko Reiner. "Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review." Cardiovascular Therapeutics 2022 (2022). https://doi.org/10.1155/2022/8129513

Merćep, I., et al. (2022) 'Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review', Cardiovascular Therapeutics, 2022. doi: 10.1155/2022/8129513

Merćep I, Friščić N, Strikić D, Reiner Ž. Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review. Cardiovascular Therapeutics [Internet]. 2022 February 10 [cited 2024 July 13];2022. doi: 10.1155/2022/8129513

I. Merćep, N. Friščić, D. Strikić and Ž. Reiner, "Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review", Cardiovascular Therapeutics, vol. 2022, February 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:539871. [Accessed: 13 July 2024]

Please login to the repository to save this object to your list.